ArticleProceedings of the National Academy of Sciences of the United States of America2021
A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike.
Open access · hybridAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 65 citations in OpenAlex.
- Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.EBioMedicine · 2022Trial
- An orthogonal transcription system enables high-efficiency rescue of measles virus-based vaccine vectors against multiple pathogens.Synthetic and systems biotechnology · 2027Article
- IRO-203: a novel intranasal COVID-19 vaccine showing immunogenicity and viral suppression in African green monkey challenge study.Scientific reports · 2026Article
- Minor differences in the untranslated regions of measles vector additional transcription units are reflected by differential immunogenicity of encoded MERS-CoV Spike antigen.Journal of virology · 2026Article
- Development of SARS-CoV-2 as a viral vector: A novel intranasal bivalent vaccine for SARS-CoV-2 and RSV.Science advances · 2025Article
- Acute induction of IFNα is responsible for the attenuation of the live measles vaccine.bioRxiv : the preprint server for biology · 2025Article
- Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective.Nature communications · 2024Article
- Article
- Article
- Article
- A murine model of post-acute neurological sequelae following SARS-CoV-2 variant infection.Frontiers in immunology · 2024Article
- Negative-Strand RNA Virus-Vectored Vaccines.Methods in molecular biology (Clifton, N.J.) · 2024Review
- A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in hamsters.Scientific reports · 2023Article
- Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases.Signal transduction and targeted therapy · 2023Review
- Oral Supplementation with AHCCPathogens (Basel, Switzerland) · 2023Article
- Recombinant measles virus expressing prefusion spike protein stabilized by six rather than two prolines is more efficacious against SARS-CoV-2 infection.Journal of medical virology · 2023Article
- A protective measles virus-derived vaccine inducing long-lasting immune responses against influenza A virus H7N9.NPJ vaccines · 2023Article
- Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity.Vaccines · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 4 institutions in 1 country.
Mijia LuDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.ORCID https://orcid.org/0000-0002-4438-980X
Piyush DravidCenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.ORCID https://orcid.org/0000-0002-4790-9591
Yuexiu ZhangDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Sheetal TrivediCenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.
Anzhong LiDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Olivia HarderDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Mahesh KcCenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.ORCID https://orcid.org/0000-0002-5177-9566
Supranee ChaiwatpongsakornCenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.ORCID https://orcid.org/0000-0003-3511-7359
Ashley ZaniDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH 43210.
Adam KenneyDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH 43210.
Cong ZengDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Chuanxi CaiDepartment of Surgery, College of Medicine, The Ohio State University, Columbus, OH 43210.ORCID https://orcid.org/0000-0003-0532-7435
Chengjin YeTexas Biomedical Research Institute, San Antonio, TX 78227.
Xueya LiangDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Masako ShimamuraCenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.
Shan-Lu LiuDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Asuncion MejiasCenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.
Octavio RamiloCenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.
Prosper N BoyakaDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.ORCID https://orcid.org/0000-0001-6857-9088
Jianming QiuDepartment of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center, Kansas City, KS 66160.ORCID https://orcid.org/0000-0001-9850-1695
Luis Martinez-SobridoTexas Biomedical Research Institute, San Antonio, TX 78227.
Jacob S YountDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH 43210.
Mark E PeeplesCenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.
Amit KapoorCenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.
Stefan NiewieskDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Jianrong LiDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210; li.926@osu.edu.
The Ohio State University · USNationwide Children's Hospital · USTexas Biomedical Research Institute · USUniversity of Kansas Medical Center · US
Funding
Transcriptome-wide base-resolution sequencing of pseudouridine in human normal and AD brain tissues-CEGS Admin supplement 2020-2021RM1HG008935 · NHGRI · UNIVERSITY OF CHICAGO · PI HE, CHUAN · 2016 to 2025
$24.4MTechnology Development Project - Increasing the complexity of ex vivo human airway models for studying immune response to viral infectionU19AI142733 · NIAID · JACKSON LABORATORY · PI Anna Karolina Palucka · 2019 to 2026
$23.1MProject 3: Responding to Changing Serological and Viral Information around COVID-19 (RESPOND)U54CA260582 · NCI · OHIO STATE UNIVERSITY · PI MCALEARNEY, ANN SCHECK, OLTZ, EUGENE M · 2020 to 2024
$10.4MProject 3: Dr. LiP01AI112524 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI LI, JIANRONG · 2015 to 2019
$6.8MMechanisms of innate resistance to virus infectionsR01AI130110 · NIAID · OHIO STATE UNIVERSITY · PI Jacob Yount · 2017 to 2026
$4.3MMessenger RNA Capping and Methylation in PneumovirusesR01AI090060 · NIAID · OHIO STATE UNIVERSITY · PI LI, JIANRONG · 2011 to 2023
$4.0MRespiratory Syncytial Virus Targeting of the Human Airway EpitheliumR01AI093848 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI PEEPLES, MARK E. · 2012 to 2023
$3.8MBorrelia burgdorferi-Induced Autoimmunity in Lyme DiseaseR01AI101175 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI STEERE, ALLEN C · 2013 to 2021
$3.6MTargeting myeloid cells for regulation of alum-based immunityR01AI145144 · NIAID · OHIO STATE UNIVERSITY · PI BOYAKA, PROSPER N · 2020 to 2024
$3.1MA novel lactic acid bacteria-based norovirus vaccineR01AI123661 · NIAID · OHIO STATE UNIVERSITY · PI BOYAKA, PROSPER N, HE, XIAOMING · 2016 to 2020
$3.0MHost response and liver disease in a hepatitis C-like virus rat modelR01AI137567 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI KAPOOR, AMIT · 2018 to 2022
$2.5MImmune correlates of protection against hepacivirus persistence.R01AI151175 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI KAPOOR, AMIT · 2021 to 2024
$2.5MNCI NIH HHS U54 CA260582NHGRI NIH HHS RM1 HG008935NHLBI NIH HHS R01 HL154001NIAID NIH HHS P01 AI112524NIAID NIH HHS R01 AI090060NIAID NIH HHS R01 AI093848NIAID NIH HHS R01 AI101175NIAID NIH HHS R01 AI112381NIAID NIH HHS R01 AI123661NIAID NIH HHS R01 AI130110NIAID NIH HHS R01 AI137567NIAID NIH HHS R01 AI145144NIAID NIH HHS R01 AI150473NIAID NIH HHS R01 AI151175NIAID NIH HHS R21 AI142256NIAID NIH HHS R21 AI146690NIAID NIH HHS R21 AI151230NIAID NIH HHS R56 AI090060NIAID NIH HHS U19 AI142733NIDDK NIH HHS R01 DK101323NIH HHS U19AI42733
Abstract
The current pandemic of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights an urgent need to develop a safe, efficacious, and durable vaccine. Using a measles virus (rMeV) vaccine strain as the backbone, we developed a series of recombinant attenuated vaccine candidates expressing various forms of the SARS-CoV-2 spike (S) protein and its receptor binding domain (RBD) and evaluated their efficacy in cotton rat, IFNAR
Indexed as
Genetic VectorsMeasles virusAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesCricetinaeDisease Models, AnimalGene ExpressionHumansImmunizationImmunogenicity, VaccineMiceMice, TransgenicRatsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, CoronavirusVaccines, Syntheticmeasles virus vectorprefusion spikeSARS-CoV-2 vaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.